AbbVie (NYSE:ABBV) Price Target Raised to $270.00

AbbVie (NYSE:ABBV) had its target price hoisted by stock analysts at Morgan Stanley from $269.00 to $270.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 24.40% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Piper Sandler reissued an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Berenberg Bank set a $275.00 price target on AbbVie in a research note on Tuesday, January 20th. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $251.56.

AbbVie Stock Performance

NYSE:ABBV opened at $217.04 on Thursday. AbbVie has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a fifty day moving average price of $223.99 and a two-hundred day moving average price of $219.14. The stock has a market capitalization of $383.59 billion, a price-to-earnings ratio of 164.42, a PEG ratio of 0.93 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the prior year, the company posted $2.16 EPS. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie will post 12.31 EPS for the current year.

Hedge Funds Weigh In On AbbVie

A number of institutional investors have recently modified their holdings of ABBV. Evolution Wealth Management Inc. purchased a new position in AbbVie during the second quarter worth about $26,000. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the 3rd quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the 2nd quarter worth about $28,000. Westend Capital Management LLC purchased a new position in shares of AbbVie during the 4th quarter worth about $29,000. Finally, Texas Capital Bancshares Inc TX acquired a new stake in shares of AbbVie in the third quarter worth approximately $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat on top and bottom line — AbbVie reported adjusted EPS of $2.71 (above consensus) and revenue of $16.62B, driven by overall revenue strength and margin expansion; this underpins the company’s raised annual outlook. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Skyrizi and Rinvoq are driving growth — both drugs grew >30% Y/Y and powered immunology revenue, helping offset Humira declines and supporting the bullish FY profit outlook. Strong uptake is a core reason management lifted 2026 profit guidance. AbbVie forecasts 2026 profit above estimates
• Positive Sentiment: Rinvoq expansion opportunity — AbbVie has filed for upadacitinib (Rinvoq) approval in vitiligo with FDA/EMA; a new indication would expand addressable market and is a potential medium-term revenue kicker. AbbVie submits regulatory applications for Rinvoq in vitiligo
• Neutral Sentiment: 2026 adjusted EPS guidance raised but caveated — management set FY 2026 adjusted EPS at $14.37–$14.57 (above consensus), which is supportive, but the range excludes acquired IPR&D and milestone costs (management warns these items are unpredictable). Full Q4 release and 2026 guidance
• Negative Sentiment: Softer Q1 2026 guide sparked the selloff — AbbVie trimmed Q1 EPS and revenue guidance (Q1 EPS range 2.97–3.01 vs. a higher consensus), and the lower near-term guide appears to be the main catalyst for today’s decline. AbbVie beats Q4; stock down despite upbeat ’26 view
• Negative Sentiment: Concerns about diversification and aesthetics/oncology weakness — investors and some analysts flagged that outside immunology (Skyrizi/Rinvoq) growth is uneven (aesthetics down ~6% FY, oncology pressure), raising questions about longer-term growth without more M&A or new launches. That debate is weighing on sentiment. AbbVie diversification concerns (Seeking Alpha)

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.